Actinium shares early ATNM-400 prostate cancer trial data at EANM

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Actinium shares early ATNM-400 prostate cancer trial data at EANM

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

October 20, 2026 8:01 AM EDT

HER3targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium225's 10-day halflife Initial threepatient cohort completed the first dose level of 1.0 µCi/kg with no doselimiting toxicities, xerostomia or Grade 3/4 hematologic adverse events observed ATNM400 advanced to the second dose level of 1.5 µCi/kg, marking continued clinical progress for a firstinclass Actinium225 antibody radiotherapy with potential across the broad mCRPC population

NEW... More